Group B streptococcal phospholipid causes pulmonary hypertension

Area of Science:

• Neonatal Medicine
• Bacterial Pathogenesis
• Cardiovascular Physiology

Background:

• Group B Streptococcus (GBS) is a leading cause of bacterial infections in newborns.
• GBS infections can lead to persistent pulmonary hypertension, compromising lung function and gas exchange.
• Pulmonary hypertension in neonates poses significant risks to survival and long-term health.

Purpose of the Study:

• To identify the specific bacterial components of Group B Streptococcus responsible for inducing pulmonary hypertension.
• To investigate the role of purified bacterial phospholipids in the development of neonatal pulmonary hypertension.
• To explore potential therapeutic strategies targeting bacterial-derived molecules in GBS-related complications.

Main Methods:

• Purification of bacterial components from Group B Streptococcus cultures.
• In vivo studies using a lamb model to assess the hypertensive effects of purified compounds.
• Administration of synthetic cardiolipin and phosphatidylglycerol to evaluate their independent impact on pulmonary arterial pressure.

Main Results:

• Specific bacterial phospholipids, cardiolipin and phosphatidylglycerol, were isolated and identified as causative agents.
• Both purified natural and synthetic forms of cardiolipin and phosphatidylglycerol induced pulmonary hypertension in the lamb model.
• These findings demonstrate a direct link between bacterial phospholipids and the development of pulmonary hypertension.

Conclusions:

• Bacterial cardiolipin and phosphatidylglycerol are key mediators of pulmonary hypertension in the context of Group B Streptococcus infection.
• Understanding this mechanism opens novel therapeutic avenues for managing GBS-induced pulmonary hypertension in neonates.
• Targeting these bacterial phospholipids could offer a new strategy to prevent or treat this severe neonatal complication.